Solan Headlines

Post-Menopausal Osteoporosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Post-Menopausal Osteoporosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 14
03:08 2023
Post-Menopausal Osteoporosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Post-Menopausal Osteoporosis pipeline constitutes 18+ key companies continuously working towards developing 18+ Post-Menopausal Osteoporosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Post-Menopausal Osteoporosis Overview

Preventing bone loss is an important concern for women in the menopause and during post-menopausal stages. Menopause significantly speeds bone loss and increases the risk for osteoporosis. Research indicates that up to 20% of bone loss can happen during these stages and approximately 1 in 10 women over the age of 60 are affected by osteoporosis worldwide.

 

Post-Menopausal Osteoporosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Post-Menopausal Osteoporosis Market.

 

The Post-Menopausal Osteoporosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Post-Menopausal Osteoporosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Post-Menopausal Osteoporosis treatment therapies with a considerable amount of success over the years. Post-Menopausal Osteoporosis Key players such as – Mabwell (Shanghai) Bioscience, Jiangsu HengRui Medicine, Eli Lilly/Transcenta Holding, Qilu Pharmaceutical, Samsung Bioepis, and others, are developing therapies for the Post-Menopausal Osteoporosis treatment 
  • Post-Menopausal Osteoporosis Emerging therapies such as – MW031, SHR-1222, Blosozumab, QL1206, SB16, and others are expected to have a significant impact on the Post-Menopausal Osteoporosis market in the coming years.  
  • Bioepis in November 2020, initiated a Phase III, randomised, double-blind, multicentre clinical study to compare the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity between SB16 (Proposed Denosumab Biosimilar) and Prolia in Postmenopausal Women with Osteoporosis

 

Route of Administration

Post-Menopausal Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Post-Menopausal Osteoporosis Pipeline Therapeutics Assessment

  • Post-Menopausal Osteoporosis Assessment by Product Type
  • Post-Menopausal Osteoporosis By Stage and Product Type
  • Post-Menopausal Osteoporosis Assessment by Route of Administration
  • Post-Menopausal Osteoporosis By Stage and Route of Administration
  • Post-Menopausal Osteoporosis Assessment by Molecule Type
  • Post-Menopausal Osteoporosis by Stage and Molecule Type

 

DelveInsight’s Post-Menopausal Osteoporosis Report covers around 18+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Post-Menopausal Osteoporosis Therapeutics Market include:

Key companies developing therapies for Post-Menopausal Osteoporosis are – Teva Pharmaceutical, Shanghai Biomabs Pharmaceutical, HEXAL, Shenzhen Salubris Pharmaceuticals, Celltrion, Mabwell (Shanghai) Bioscience Co., Ltd., PhytoHealth, Luye Pharma, Sandoz International GmbH, Addpharma, and others.

 

Emerging Post-Menopausal Osteoporosis Drugs Under Different Phases of Clinical Development Include:

  • MW031: Mabwell (Shanghai) Bioscience
  • SHR-1222: Jiangsu HengRui Medicine
  • Blosozumab: Eli Lilly/Transcenta Holding
  • QL1206: Qilu Pharmaceutical
  • SB16: Samsung Bioepis

 

Get a Free Sample PDF Report to know more about Post-Menopausal Osteoporosis Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-pipeline-insight

 

Post-Menopausal Osteoporosis Pipeline Analysis:

The Post-Menopausal Osteoporosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Post-Menopausal Osteoporosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Menopausal Osteoporosis Treatment.
  • Post-Menopausal Osteoporosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Post-Menopausal Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Menopausal Osteoporosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Post-Menopausal Osteoporosis product details are provided in the report. Download the Post-Menopausal Osteoporosis pipeline report to learn more about the emerging Post-Menopausal Osteoporosis therapies

 

Post-Menopausal Osteoporosis Pipeline Market Drivers

  • Increasing prevalence of osteoporosis in postmenopausal women
  • Growing awareness about osteoporotic care

 

Post-Menopausal Osteoporosis Pipeline Market Barriers

  • Need for novel therapies
  • Requirement of potential improvements in patient management and physician training

 

Scope of Post-Menopausal Osteoporosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Post-Menopausal Osteoporosis Companies: Mabwell (Shanghai) Bioscience, Jiangsu HengRui Medicine, Eli Lilly/Transcenta Holding, Qilu Pharmaceutical, Samsung Bioepis, and others
  • Key Post-Menopausal Osteoporosis Therapies: MW031, SHR-1222, Blosozumab, QL1206, SB16, and others
  • Post-Menopausal Osteoporosis Therapeutic Assessment: Post-Menopausal Osteoporosis current marketed and Post-Menopausal Osteoporosis emerging therapies
  • Post-Menopausal Osteoporosis Market Dynamics: Post-Menopausal Osteoporosis market drivers and Post-Menopausal Osteoporosis market barriers 

 

Request for Sample PDF Report for Post-Menopausal Osteoporosis Pipeline Assessment and clinical trials

 

Table of Contents

1

Post-Menopausal Osteoporosis Report Introduction

2

Post-Menopausal Osteoporosis Executive Summary

3

Post-Menopausal Osteoporosis Overview

4

Post-Menopausal Osteoporosis- Analytical Perspective In-depth Commercial Assessment

5

Post-Menopausal Osteoporosis Pipeline Therapeutics

6

Post-Menopausal Osteoporosis Late Stage Products (Phase II/III)

7

Post-Menopausal Osteoporosis Mid Stage Products (Phase II)

8

Post-Menopausal Osteoporosis Early Stage Products (Phase I)

9

Post-Menopausal Osteoporosis Preclinical Stage Products

10

Post-Menopausal Osteoporosis Therapeutics Assessment

11

Post-Menopausal Osteoporosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Post-Menopausal Osteoporosis Key Companies

14

Post-Menopausal Osteoporosis Key Products

15

Post-Menopausal Osteoporosis Unmet Needs

16 

Post-Menopausal Osteoporosis Market Drivers and Barriers

17

Post-Menopausal Osteoporosis Future Perspectives and Conclusion

18

Post-Menopausal Osteoporosis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Post-Menopausal Osteoporosis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services